

IPR and Innovation

1. [US industry waiting to hear PM Narendra Modi's stand on Intellectual Property Rights](#) – The Economic Times
2. [Dr Reddy's settles patent litigation on Kuvan tablets](#) – Business Standard

Access to Healthcare

1. [Public health gets focused attention](#) – Deccan Herald

Medical & Regulatory

1. [Pharma, healthcare sector under scanner as CCI decides to investigate unfair practices](#) – DNA

Others

1. [The future of health in India](#) – Reuters
 2. [Pharma firms line up a slew of US M&As](#) – DNA
-

IPR and Innovation

1. [US industry waiting to hear PM Narendra Modi's stand on Intellectual Property Rights](#) – The Economic Times
The US industry will wait to hear the [Narendra Modi](#) government's stand on protection of [Intellectual Property](#) Rights when PM meets business leaders in New York and [Silicon Valley](#) this week. Modi's interactions will provide him a better understanding of the importance of IPR, US government officials said, hoping India would appreciate the concerns of US enterprises. More than one-third of the US economy is based on IP-intensive industries. The US has urged successive Indian governments to create a regime that will protect the intellectual property rights of its enterprises that invest in India, especially pharmaceutical companies. US officials pointed out that they prefer a predictable IPR regime for its innovators.
2. [Dr Reddy's settles patent litigation on Kuvan tablets](#) – Business Standard
The California-based BioMarin Pharmaceutical has entered into a settlement agreement with [Dr Reddy's Laboratories](#) to resolve patent litigation in the US regarding Kuvan, the former's 100mg oral tablets. According to a statement issued by BioMarin, the US drugmaker said it will grant Dr Reddy's a non-exclusive licence to its patents on Kuvan (sapropterin dihydrochloride) allowing the Indian drug maker to market a generic version of Kuvan 100mg tablets in the US at a later stage, which is expected to be more than five years from now.

Access to Healthcare

1. [Public health gets focused attention](#) – Deccan Herald
The government's plan to give focused attention to 184 districts in the country in the delivery of reproductive and child healthcare can help improve the country's overall performance in this crucial area of public health. These districts have been selected for the initiative because they have been the worst performers with respect to maternal and infant mortality rates. The

announcement was made by Prime Minister Narendra Modi at the Call to Action summit in Delhi of countries that account for most maternal and infant deaths. The aim of the programme is to stop such deaths by 2030. The plan might seem too long-term. But it may be considered as only a realistic time target in view of the scale of infrastructure and investment needed to achieve the goal. Longer-term plans have failed to achieve their targets in the past.

Medical & Regulatory

1. [Pharma, healthcare sector under scanner as CCI decides to investigate unfair practices](#) – DNA
To look into the issues in pharma and [healthcare](#) services in the national capital region, the [Competition Commission of India](#) is going to do a detailed study that will cover public and private hospitals, insurance companies, pharma companies, doctors and their contacts, among others. The study will be done from competition perspective to check business malpractices, and the regulator has already invited Expression of Interest (EoI) from the companies.

Others

1. [The future of health in India](#) – Reuters
Is India a healthy nation? It is an uncomfortable question, particularly so when it is directed at a nation known for its back-breaking burden of diseases. The question might even be dismissed as an irrelevant one, but that would be a mistake. The issue it raises is very real, but the search to answer that question leads us to the revelation that India is ready to develop an acceptable answer regarding population health.
2. [Pharma firms line up a slew of US M&As](#) – DNA
Despite slowing down of drug approval process in the US, Indian pharma companies are showing increasing appetite in snapping up companies in that market. While several deals have been stuck in recent past, Indian companies are looking at acquiring assets with niche products portfolio and strong pipeline to fasten the approvals process, according to pharma analysts.